Insights and Ideas

Whitepapers, case studies, and other helpful resources to support outcomes-based healthcare

Becoming HIPAA Compliant: Our Investment in the Future of Healthcare

Oct. 11, 2017 hipaa Best Practices About

Peter Saul, director of emerging solutions, describes why we went through the process to become compliant with the Health Insurance Portability and Accountability Act of 1996, better known as HIPAA. 


Vascular Disease Highlights from the Chicago EndoVascular Conference: A Chat with Our Experts

Oct. 3, 2017 Medical Devices

Procured Health medical device experts Vikram Karandikar and Kelsey Peterson recently attended the Chicago EndoVascular Conference (CVC). Below they trade thoughts about some recent advances in the field.


Uncover Inappropriate Exparel Utilization

US health systems spend $270M annually on Exparel, but has it shown superiority over older analgesics? This case study describes how one health system used clinical evidence to work with physicians to eliminate unnecessary Exparel utilization.

Read this article to: 

• Learn how one organization saved nearly $1M off a base spend of $1.2M 

• See what the evidence says about Exparel's relationship to improved outcomes   

• Discover how mapping your spend and utilization data to clinical evidence can drive change


Strategies to Reduce Care and Cost Variation in Spine

The last five years have brought a massive surge in new spine technology, and this growth will continue for the foreseeable future. At the same time, the cost of caring for spine patients is outpacing reimbursement rates at an ever-increasing speed. 

Key takeaways in this white paper include: 

• Why high costs, high procedural volumes, variable treatments and wide-ranging outcomes are creating an opportunity for improvements in spine care

• Which revolutionary technologies warrant a price premium  

• How the DISC methodology has helped health systems realize significant savings while reducing procedural variation 


Leading Health Systems Overhaul New Technology Requests With Integrated Governance Model

Health systems are often more paralyzed by “evolutionary” new technology requests than by those that are revolutionary. To address the waste that this confusion can lead to, health systems must evaluate their existing governance models and reinvigorate their technology review processes to ensure that the right teams and governance structures are in place to align with organizational goals.


Ask Procured Health: Which novel oral anticoagulant is best for venous thromboembolism?

Sept. 18, 2017 Pharmacy Pharmacy Leaders

In talking to healthcare leaders about drug utilization, I’ve fielded many questions concerning the application of clinical evidence to specific drugs and drug categories. I address one popular topic below.

DEAR PROCURED HEALTH: I would like to standardize my hospital formulary to a single novel oral anticoagulant (NOAC). Is there evidence demonstrating the best option for treating and preventing venous thromboembolism (VTE)? – NEEDING NOAC KNOWLEDGE


Procured Health Podcast, Episode One: Our Company Values

We are very excited to introduce our podcast, where we'll talk about the latest trends in the industry, go in-depth on the evidence for top-of-mind medical products and drugs, give you an inside look at who we are as a company, and more. 

For our first episode, Lauren Sroka on the Procured Health talent team sits down with CEO Hani Elias for a very insightful discussion about how we developed our values and how they guide our culture. 


Exploring the Frontier of Healthcare Change: Procured Health Leadership Roundtable

Sept. 7, 2017 Clinical Leadership

A unique think tank for innovative solutions

The Procured Health Leadership Roundtable gathers top healthcare leaders in the country to collaborate, share, and solve healthcare's biggest challenges in an interactive forum. Roundtable attendees took valuable insights and actions back to their organizations.


Evidence Insight Spotlight: The da Vinci Surgical System

The da Vinci Surgical System is a surgeon-controlled, minimally invasive robotic platform used to perform a range of complex procedures. The da Vinci Xi was introduced in 2014 to address perceived design shortcomings of its predecessor, the da Vinci Si. However, these improvements come at a higher cost. 

Download this case study to: 

• Learn what issues the da Vinci Xi was designed to address

• Explore how the Xi's modifications impact clinical and operational outcomes 

• Discover whether these outcomes justify the Xi's price tag


Ask Procured Health: Should hospitals add Entresto to formulary?

In talking to healthcare leaders about drug utilization, I’ve fielded many questions concerning the application of clinical evidence to specific drugs and drug categories. I address one popular topic below.

DEAR PROCURED HEALTH: I’m a pharmacy clinical coordinator, and my hospital’s cardiologists are clamoring for Entresto (sacubitril/valsartan) to treat patients with chronic heart failure. They point to strong efficacy data and last year’s updated American College of Cardiology/American Heart Association guidelines that recommend it over ACE inhibitors and ARBs. Should we add Entresto to our inpatient formulary? – UNCLEAR ABOUT ENTRESTO